DR5 Antibody (7F4-F8-G11): sc-517559

DR5 Antibody (7F4-F8-G11) is a mouse monoclonal IgG antibody that detects DR5 in mouse, rat, and human samples through western blotting (WB) and immunofluorescence (IF) applications. Anti-DR5 antibody (7F4-F8-G11) is available in a non-conjugated form, allowing for versatile experimental setups. DR5, also known as death receptor 5, plays a crucial role in mediating apoptosis through interaction with the cytokine TRAIL (TNF-related apoptosis-inducing ligand). This interaction is vital for regulating programmed cell death, which is essential for maintaining cellular homeostasis and eliminating damaged or cancerous cells. DR5′s ability to initiate apoptosis makes DR5 a significant target in cancer therapy, as enhancing DR5 signaling pathway can promote the death of tumor cells. Additionally, DR5 is part of the larger TNF receptor superfamily, which includes other important receptors involved in immune responses and cell survival. Understanding DR5 function and signaling mechanisms is critical for developing therapeutic strategies aimed at manipulating apoptosis in various diseases, particularly in oncology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DR5 Antibody (7F4-F8-G11) References:

1. HLA-B40-, HLA-Cw3-, and HLA-DR5-associated susceptibility to amiodarone-induced thyroid dysfunction.  |  Erdoğan, MF., et al. 2000. Thyroid. 10: 369-70. PMID: 10807068
2. DR5 knockout mice are compromised in radiation-induced apoptosis.  |  Finnberg, N., et al. 2005. Mol Cell Biol. 25: 2000-13. PMID: 15713653
3. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.  |  Pavet, V., et al. 2010. Cancer Res. 70: 1101-10. PMID: 20103630
4. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.  |  Surget, S., et al. 2012. Cancer Res. 72: 4562-73. PMID: 22738917
5. The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells.  |  Liu, F., et al. 2015. Biomed Pharmacother. 70: 41-5. PMID: 25776477
6. A role for caspase-8 and TRAIL-R2/DR5 in ER-stress-induced apoptosis.  |  Muñoz-Pinedo, C. and López-Rivas, A. 2018. Cell Death Differ. 25: 226. PMID: 28984868
7. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.  |  Yue, D. and Sun, X. 2019. Cancer Biol Ther. 20: 284-294. PMID: 30359552
8. Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53.  |  Zhou, X., et al. 2020. Cancers (Basel). 12: PMID: 32899699
9. Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis.  |  Abd-Rabou, AA., et al. 2021. Asian Pac J Cancer Prev. 22: 2855-2865. PMID: 34582654
10. Strophanthidin Induces Apoptosis of Human Lung Adenocarcinoma Cells by Promoting TRAIL-DR5 Signaling.  |  Tian, X., et al. 2024. Molecules. 29: PMID: 38398629

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DR5 Antibody (7F4-F8-G11) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-DR5 Antibody (7F4-F8-G11) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DR5 Antibody (7F4-F8-G11) Specifications

Alternate Product Name: DR5

Product Clone Name: 7F4-F8-G11

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG

Amino Acids:

Epitope Target: DR5

Epitope Species: human

Product Reactivity/Detection: DR5

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF

Vialing Information: Each vial contains 100 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for DR5 Antibody (7F4-F8-G11): N/A

The preferred DR5 antibody is DR5 Antibody (D-6): sc-166624.